問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Linkou Chang Gung Medical Foundation (在職)

Division of Rheumatology

Division of General Internal Medicine

Division of Dermatology

Division of Ophthalmology

更新時間：2023-09-19

郭昶甫Kuo, Chang-Fu
  • Principal Investigator
  • Clinical Trial Experience (year) 17 years 10 個月

  • vera0523@gmail.com

Recruiting Trial

19Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

郭昶甫

Linkou Chang Gung Medical Foundation

Division of Rheumatology

List

37Cases

2023-07-01 - 2027-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2007-04-01 - 2011-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2015-09-01 - 2019-12-31

Phase III

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNFα Refractory Subjects With Active Radiographic Axial Spondyloarthritis

  • Condition/Disease

    Active Radiographic Axial Spondyloarthritis

  • Test Drug

    STELARA

Participate Sites
10Sites

Terminated10Sites

2015-09-01 - 2020-05-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2015-09-01 - 2018-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

羅淑芬
Linkou Chang Gung Medical Foundation

Division of Rheumatology

2015-10-15 - 2020-06-30

Phase II

A Multicenter, Randomized, Double-blind, Placebo-controlled, Proof-of-Concept Study of Ustekinumab in Subjects With Active Systemic Lupus Erythematosus

  • Condition/Disease

    Active Systemic Lupus Erythematosus

  • Test Drug

    STELARA

Participate Sites
6Sites

Terminated4Sites

Study ended1Sites

藍忠亮
China Medical University Hospital-Taipei

未分科

藍忠亮
China Medical University Hospital

2016-06-06 - 2022-03-10

Phase III

A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) to Placebo in Subjects With Moderately to Severely Active Rheumatoid Arthritis Who Are on a Stable Dose of Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) and Have an Inadequate Response to csDMARDs

  • Condition/Disease

    Rheumatoid Arthritis

  • Test Drug

    ABT-494

Participate Sites
8Sites

Terminated7Sites

黃春明
China Medical University Hospital-Taipei

未分科

2016-10-01 - 2020-03-15

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

方耀凡
Linkou Chang Gung Medical Foundation

Division of Rheumatology

2008-03-01 - 2010-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2007-05-01 - 2009-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

Study ended11Sites

1 2 3 4
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB